Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice

Sneha Patel, Anand Kumthekar

Research output: Contribution to journalReview articlepeer-review

Abstract

Psoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population. In the last 20 years, the therapeutic options for PsA have increased exponentially with the availability of tumor necrosis factor-alpha (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-12/23 inhibitors and Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) inhibitors. The articular and extra-articular manifestations of PsA usually dictate the treatment choice but important consideration must be given to the corresponding co-morbidities while deciding the drug therapy due to associated safety profile, effect on disease activity, etc. This review provides a comprehensive review of common co-morbidities in PsA and how they can influence treatment choices.

Original languageEnglish (US)
Pages (from-to)49-71
Number of pages23
JournalRheumatology and Therapy
Volume9
Issue number1
DOIs
StatePublished - Feb 2022

Keywords

  • Co-morbidities
  • Drug therapy
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice'. Together they form a unique fingerprint.

Cite this